Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- IDIA.SW
- Price
- 1.90
- Stock movement down
- -0.03 (-1.55%)
- Company name
- Idorsia Ltd
- Exchange
- (SW ,
- Currency
- CHF )
- Sector
- Healthcare >Biotechnology
- Market cap
- 357.82M
- Ent value
- 1.66B
- Price/Sales
- 5.07
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -11.37%
- 1 year return
- -4.52%
- 3 year return
- -47.15%
- 5 year return
- -42.47%
- 10 year return
- -
Last updated: 2025-06-22
DIVIDENDS
IDIA.SW does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 5.07 |
| Price to Book | - |
| EV to Sales | 23.55 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 188.33M |
| EPS (TTM) | -1.57 |
| FCF per share (TTM) | -2.35 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 70.62M |
| Gross profit (TTM) | 38.78M |
| Operating income (TTM) | -385.38M |
| Net income (TTM) | -296.39M |
| EPS (TTM) | -1.57 |
| EPS (1y forward) | -0.17 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 54.92% |
| Operating margin (TTM) | -545.69% |
| Profit margin (TTM) | -419.68% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 77.30M |
| Net receivables | 23.09M |
| Total current assets | 198.89M |
| Goodwill | 0.00 |
| Intangible assets | 13.60M |
| Property, plant and equipment | 0.00 |
| Total assets | 432.60M |
| Accounts payable | 13.32M |
| Short/Current long term debt | 1.26B |
| Total current liabilities | 317.14M |
| Total liabilities | 1.38B |
| Shareholder's equity | -949.93M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -427.18M |
| Capital expenditures (TTM) | 18.16M |
| Free cash flow (TTM) | -445.34M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -68.51% |
| Return on Invested Capital | 39.52% |
| Cash Return on Invested Capital | 59.38% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.93 |
| Daily high | 2.04 |
| Daily low | 1.90 |
| Daily Volume | 1.80M |
| All-time high | 33.62 |
| 1y analyst estimate | 1.53 |
| Beta | 1.29 |
| EPS (TTM) | -1.57 |
| Dividend per share | - |
| Ex-div date | 16 Jun 2017 |
| Next earnings date | 30 Oct 2025 |
Downside potential
Loading...
Downside potential data
| IDIA.SW | S&P500 | |
| Current price drop from All-time high | -94.35% | -3.04% |
| Highest price drop | -98.12% | -56.47% |
| Date of highest drop | 20 Dec 2024 | 9 Mar 2009 |
| Avg drop from high | -47.07% | -11.04% |
| Avg time to new high | 54 days | 12 days |
| Max time to new high | 1362 days | 1805 days |
COMPANY DETAILS
Marketcap
357.82M
Marketcap category
Small-cap
Description
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant) for the treatment of adult patients with insomnia. The company has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and commercialize PIVLAZ. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Switzerland
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Allschwil, Switzerland – September 10, 2025Idorsia Ltd (SIX: IDIA) shares new analyses of daridorexant for patients with insomnia and further characterizes insomnia disorder at World Sleep 2025, deliv...
September 10, 2025
Analysis of the FAERS database shows that the real-world abuse potential of the DORA class is very low and markedly less than those seen for other scheduled and non-scheduled insomnia therapies Allsch...
September 8, 2025
Idorsia Ltd (SIX: IDIA) announces a first-of-its-kind initiative with the Stanford Hypertension Center and Duke Heart Center to launch IMPACT-HTN, a new three-phase program to transform and modernize ...
September 5, 2025
Idorsia will host a live investor Q&A webcast and conference call following the publication of the OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension ther...
September 3, 2025
Allschwil, Switzerland – September 1, 2025Idorsia Ltd (SIX: IDIA) continues its commitment to furthering the science of sleep and insomnia with a symposium and eight poster presentations at World Slee...
September 1, 2025
Allschwil, Switzerland – August 28, 2025Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting the endot...
August 28, 2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 27, 2025Idorsia Ltd (SIX: IDIA) settled the repurchase offer for its outstanding CHF 204* million convertible bonds maturing ...
August 27, 2025
The report highlights opportunities in strategic investment and optimizing trial locations. It identifies key clinical trial trends and successes globally, aiding competitive positioning and efficient...
August 26, 2025
The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the endothelin pathway.Endothelin is upregulated in hypertension and is a fundament...
August 19, 2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 19, 2025Idorsia Ltd (SIX: IDIA) announces the end results of the repurchase offer for its outstanding CHF 204* million conver...
August 19, 2025
Next page